{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-003407","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.909015+00:00","generated_at":"2026-05-24T04:27:12.702411+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%","bullets":["Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.","License revenue $1.8M, up 35.3% YoY, driven by changes in sales of Mayne licensed products.","Total operating expenses $6.5M, down 33.6% from $9.8M, due to cost cuts and transition to royalty model.","Cash and cash equivalents $5.1M as of December 31, 2024.","Company continues to evaluate strategic alternatives including M&A, sale of assets, or other transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-003407","json":"https://secwatch.observer/filing/0001013762-25-003407.json","markdown":"https://secwatch.observer/filing/0001013762-25-003407.md","text":"https://secwatch.observer/filing/0001013762-25-003407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/0001013762-25-003407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000101376225003407/ea0235200-8k_therap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:27:12.702411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}